Brana I, et al. Br. J. Cancer (2014) cited as Ref 581 in DOI: 10.1038/s41392-020-0110-5 (Q9844)
Revision as of 22:04, 20 May 2020 by Admin (talk | contribs) (Created claim: Property:P93: A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206 the mTOR inhibitor ridaforolimus or the NOTCH inhibitor MK-0752 in patients wit...)
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Brana I, et al. Br. J. Cancer (2014) cited as Ref 581 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Brana I
0 references
2014
0 references
Br. J. Cancer
0 references
111
0 references
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206 the mTOR inhibitor ridaforolimus or the NOTCH inhibitor MK-0752 in patients with advanced solid tumours (English)
0 references
